DL-Homocysteic acidCAS# 504-33-6 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 504-33-6 | SDF | Download SDF |
PubChem ID | 7018167 | Appearance | Powder |
Formula | C4H9NO5S | M.Wt | 183.18 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R)-2-azaniumyl-4-sulfonatobutanoate | ||
SMILES | C(CS(=O)(=O)[O-])C(C(=O)[O-])[NH3+] | ||
Standard InChIKey | VBOQYPQEPHKASR-GSVOUGTGSA-M | ||
Standard InChI | InChI=1S/C4H9NO5S/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H,8,9,10)/p-1/t3-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | DL-Homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo. |
Targets | Calcium Channel |
In vitro | Effect of dl-homocysteic acid on W/O microemulsions of potassium naphthenate/1-octanol-n-heptane.[Pubmed: 15694443]J Colloid Interface Sci. 2005 Mar 1;283(1):231-7.The effect of DL-Homocysteic acid (DL-2-amino-4-sulfonobutyric acid) on W/O microemulsion of potassium naphthenate (80%) and naphthenic acid (20%) in mixed solvent (1-octanol and n-heptane) has been found in four phases: (1) Interaction between the amino acid molecules and the polar head groups of the surfactant through hydrogen bonding enhances solubilization in the aqueous cores. (2) The interaction results in the growth of the microemulsion droplets and the homogenization of the particle size distribution. (3) The microstructure of the solubilized water remains unchanged, except that the polarity of the interface is affected. (4) The transition point is reduced to lower water content. A possible mechanism is proposed. |
In vivo | Cardiorespiratory effects of DL-homocysteic acid in caudal ventrolateral medulla.[Pubmed: 2646953]Am J Physiol. 1989 Mar;256(3 Pt 2):H688-96.
DL-Homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo.[Pubmed: 11935257]Acta Neuropathol. 2002 May;103(5):428-36.Excitotoxicity, autoimmunity and free radicals have been postulated to play a role in the pathomechanism of amyotrophic lateral sclerosis (ALS), the most frequent motor neuron disease. Altered calcium homeostasis has already been demonstrated in Cu/Zn superoxide dismutase transgenic animals, suggesting a role for free radicals in the pathogenesis of ALS, and in passive transfer experiments, modeling autoimmunity. These findings also suggested that yet-confined pathogenic insults, associated with ALS, could trigger the disruption of calcium homeostasis of motor neurons. |
DL-Homocysteic acid Dilution Calculator
DL-Homocysteic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.4591 mL | 27.2956 mL | 54.5911 mL | 109.1822 mL | 136.4778 mL |
5 mM | 1.0918 mL | 5.4591 mL | 10.9182 mL | 21.8364 mL | 27.2956 mL |
10 mM | 0.5459 mL | 2.7296 mL | 5.4591 mL | 10.9182 mL | 13.6478 mL |
50 mM | 0.1092 mL | 0.5459 mL | 1.0918 mL | 2.1836 mL | 2.7296 mL |
100 mM | 0.0546 mL | 0.273 mL | 0.5459 mL | 1.0918 mL | 1.3648 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Aminopyridine
Catalog No.:BCC5267
CAS No.:504-24-5
- Orcinol
Catalog No.:BCN5612
CAS No.:504-15-4
- (-)-di-de-Omethylgrandisin
Catalog No.:BCN7872
CAS No.:50393-98-1
- Cyclo(Phe-Gly)
Catalog No.:BCN2431
CAS No.:5037-75-2
- Apixaban
Catalog No.:BCC2295
CAS No.:503612-47-3
- Pentamidine dihydrochloride
Catalog No.:BCC5194
CAS No.:50357-45-4
- glucagon receptor antagonists 1
Catalog No.:BCC1593
CAS No.:503559-84-0
- NU7441 (KU-57788)
Catalog No.:BCC3679
CAS No.:503468-95-9
- 3'-Galloylquercitrin
Catalog No.:BCN8254
CAS No.:503446-90-0
- N-Methylflindersine
Catalog No.:BCN3641
CAS No.:50333-13-6
- Vilanterol trifenatate
Catalog No.:BCC4031
CAS No.:503070-58-4
- Vilanterol
Catalog No.:BCC4030
CAS No.:503068-34-6
- 3-Nitropropionic acid
Catalog No.:BCC6303
CAS No.:504-88-1
- Juglanin
Catalog No.:BCN6505
CAS No.:5041-67-8
- Isoliquiritin
Catalog No.:BCN5945
CAS No.:5041-81-6
- Isorhamnetin-3-O-beta-D-Glucoside
Catalog No.:BCN1247
CAS No.:5041-82-7
- 1,5,6-Trihydroxyxanthone
Catalog No.:BCN7642
CAS No.:5042-03-5
- Methyl 2alpha-hydroxyhardwickiate
Catalog No.:BCN7595
CAS No.:50428-93-8
- GW441756
Catalog No.:BCC5093
CAS No.:504433-23-2
- Araneosol
Catalog No.:BCN5613
CAS No.:50461-86-4
- Homopiperazine
Catalog No.:BCC8995
CAS No.:505-66-8
- 3-(Carboxymethylamino)propanoic acid
Catalog No.:BCN1791
CAS No.:505-72-6
- Fenspiride HCl
Catalog No.:BCC4659
CAS No.:5053-08-7
- Columbianadin
Catalog No.:BCN1275
CAS No.:5058-13-9
Effect of dl-homocysteic acid on W/O microemulsions of potassium naphthenate/1-octanol-n-heptane.[Pubmed:15694443]
J Colloid Interface Sci. 2005 Mar 1;283(1):231-7.
The effect of DL-Homocysteic acid (DL-2-amino-4-sulfonobutyric acid) on W/O microemulsion of potassium naphthenate (80%) and naphthenic acid (20%) in mixed solvent (1-octanol and n-heptane) has been found in four phases: (1) Interaction between the amino acid molecules and the polar head groups of the surfactant through hydrogen bonding enhances solubilization in the aqueous cores. (2) The interaction results in the growth of the microemulsion droplets and the homogenization of the particle size distribution. (3) The microstructure of the solubilized water remains unchanged, except that the polarity of the interface is affected. (4) The transition point is reduced to lower water content. A possible mechanism is proposed.
DL-Homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo.[Pubmed:11935257]
Acta Neuropathol. 2002 May;103(5):428-36.
Excitotoxicity, autoimmunity and free radicals have been postulated to play a role in the pathomechanism of amyotrophic lateral sclerosis (ALS), the most frequent motor neuron disease. Altered calcium homeostasis has already been demonstrated in Cu/Zn superoxide dismutase transgenic animals, suggesting a role for free radicals in the pathogenesis of ALS, and in passive transfer experiments, modeling autoimmunity. These findings also suggested that yet-confined pathogenic insults, associated with ALS, could trigger the disruption of calcium homeostasis of motor neurons. To test the possibility that excitotoxic processes may also be able to increase calcium in motor neurons, we applied the glutamate analogue DL-Homocysteic acid to the spinal cord of rats in vivo and analyzed the calcium distribution of the motor neurons over a 24-h survival period by electron microscopy. Initially, an elevated cytoplasmic calcium level, with no morphological sign of degeneration, was noticed. Later, increasing calcium accumulation was seen in different cellular compartments with characteristic features of alteration at different survival times. This calcium accumulation in organelles was paralleled by their progressive degeneration, which culminated in cell death by the end of the observation time. These findings confirm that increased calcium also plays a role in excitotoxic lesion of motor neurons, in line with previous studies documenting the involvement of calcium ions in motor neuronal injury in other models of the disease as well as elevated calcium in biopsy samples from ALS patients. We suggest that intracellular calcium might be responsible for the interplay between the different pathogenic processes resulting in a uniform clinicopathological picture of the disease.
Cardiorespiratory effects of DL-homocysteic acid in caudal ventrolateral medulla.[Pubmed:2646953]
Am J Physiol. 1989 Mar;256(3 Pt 2):H688-96.
We carried out experiments in urethan-anesthetized rats to determine 1) whether increasing the activity of small groups of neurons in the caudal ventrolateral medulla (CVLM) by injecting picomoles of an excitatory amino acid altered cardiovascular and/or respiratory homeostasis and 2) whether the depressor responses after chemical excitation in the CVLM were elicited only from the immunohistochemically identified catecholamine-containing cell group. In discrete sites in the CVLM, unilateral injections of 1-12 nl (20-240 pmol) of DL-Homocysteic acid (DLH; 20 mM, pH 7.4) selectively or concomitantly inhibited arterial pressure, heart rate, and diaphragm electromyogram (EMG) activity. In the region in which chemical excitation slowed breathing, units were recorded extracellularly that discharged with respiratory periodicity. Sites where the smallest volumes of DLH decreased arterial pressure were located outside the immunohistochemically identified DBH-positive cell bodies. These data suggest that either the same or neighboring neurons in the CVLM are involved in the central neural circuitry for both cardiovascular and respiratory control and that cells other than the catecholaminergic cell group are important in medullary depressor responses.